Management of Diabetic Foot Infections in an Era of Increasing Microbial Resistance

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2009 Aug 25

PMID 19698281

Citations 7

Authors

Sandra Bliss Nelson

Affiliations

Soon will be listed here.

Abstract

Diabetic foot infections cause substantial morbidity, incur significant costs, and may lead to amputation. Resistant organisms, particularly methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negative organisms, are becoming more prevalent. Optimal management of diabetic foot infections is multimodal, and includes not only antimicrobial therapy but also biomechanical support and offloading, local wound care, glycemic control, assessment and treatment of underlying vascular disease, and surgical therapy when warranted. Antimicrobial therapy should be targeted at the likely etiologic agents and should take into consideration the depth and severity of infection. With expansion of the reservoir of resistant organisms, obtaining reliable deep cultures can help focus antimicrobial therapy against the dominant pathogens. Newer agents against resistant gram-positive and gram-negative organisms show promise in the treatment of diabetic foot infections.

Citing Articles

Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance.

Alenazi F, Khan M Acta Diabetol. 2025; 62(3):303-321.

PMID: 39760785 DOI: 10.1007/s00592-024-02438-3.

Osteomyelitis in diabetic foot: A comprehensive overview.

Giurato L, Meloni M, Izzo V, Uccioli L World J Diabetes. 2017; 8(4):135-142.

PMID: 28465790 PMC: 5394733. DOI: 10.4239/wjd.v8.i4.135.

Emergence of multi drug resistant bacteria in diabetic patients with lower limb wounds.

Xavier W, Sukumaran M, Varma A, Kumar H, Chellan G Indian J Med Res. 2014; 140(3):435-7.

PMID: 25366213 PMC: 4248392.

Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.

Schaper N, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P Infection. 2012; 41(1):175-86.

PMID: 23180507 PMC: 3566391. DOI: 10.1007/s15010-012-0367-x.

Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.

Reygaert W Ther Clin Risk Manag. 2010; 6:419-30.

PMID: 20856688 PMC: 2940750. DOI: 10.2147/tcrm.s9117.

References

Tentolouris N, Jude E, Smirnof I, Knowles E, Boulton A . Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med. 1999; 16(9):767-71. DOI: 10.1046/j.1464-5491.1999.00132.x. View

Lipsky B, Holroyd K, Zasloff M . Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis. 2008; 47(12):1537-45. DOI: 10.1086/593185. View

Citron D, Goldstein E, Merriam C, Lipsky B, Abramson M . Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007; 45(9):2819-28. PMC: 2045270. DOI: 10.1128/JCM.00551-07. View

Legat F, Krause R, Zenahlik P, Hoffmann C, Scholz S, Salmhofer W . Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chemother. 2005; 49(10):4368-71. PMC: 1251535. DOI: 10.1128/AAC.49.10.4368-4371.2005. View

Stein G, Schooley S, Peloquin C, Missavage A, Havlichek D . Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007; 60(4):819-23. DOI: 10.1093/jac/dkm271. View

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K . High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2006; 50(1):18-25. DOI: 10.1007/s00125-006-0491-1. View

Oberdorfer K, Swoboda S, Hamann A, Baertsch U, Kusterer K, Born B . Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother. 2004; 54(4):836-9. DOI: 10.1093/jac/dkh412. View

Berendt A, Peters E, Bakker K, Embil J, Eneroth M, Hinchliffe R . Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008; 24 Suppl 1:S145-61. DOI: 10.1002/dmrr.836. View

Richard J, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M . Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008; 34(4 Pt 1):363-9. DOI: 10.1016/j.diabet.2008.02.005. View

10.

Slater R, Lazarovitch T, Boldur I, Ramot Y, Buchs A, Weiss M . Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med. 2004; 21(7):705-9. DOI: 10.1111/j.1464-5491.2004.01221.x. View

11.

Stanaway S, Johnson D, Moulik P, Gill G . Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract. 2006; 75(1):47-50. DOI: 10.1016/j.diabres.2006.05.021. View

12.

Goldstein E, Citron D, Warren Y, Tyrrell K, Merriam C, Fernandez H . In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother. 2006; 50(8):2875-9. PMC: 1538693. DOI: 10.1128/AAC.00286-06. View

13.

Lipsky B . Medical treatment of diabetic foot infections. Clin Infect Dis. 2004; 39 Suppl 2:S104-14. DOI: 10.1086/383271. View

14.

Wagner A, Reike H, Angelkort B . [Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections]. Dtsch Med Wochenschr. 2001; 126(48):1353-6. DOI: 10.1055/s-2001-18655. View

15.

Lavery L, Armstrong D, Wunderlich R, Mohler M, Wendel C, Lipsky B . Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006; 29(6):1288-93. DOI: 10.2337/dc05-2425. View

16.

Chang S, Sievert D, Hageman J, Boulton M, Tenover F, Downes F . Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003; 348(14):1342-7. DOI: 10.1056/NEJMoa025025. View

17.

Dinh M, Abad C, Safdar N . Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis. 2008; 47(4):519-27. PMC: 7450707. DOI: 10.1086/590011. View

18.

Hartemann-Heurtier A, Robert J, Jacqueminet S, Ha Van G, Golmard J, Jarlier V . Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med. 2004; 21(7):710-5. DOI: 10.1111/j.1464-5491.2004.01237.x. View

19.

Senneville E, Lombart A, Beltrand E, Valette M, Legout L, Cazaubiel M . Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care. 2008; 31(4):637-42. DOI: 10.2337/dc07-1744. View

20.

Dowd S, Wolcott R, Sun Y, McKeehan T, Smith E, Rhoads D . Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One. 2008; 3(10):e3326. PMC: 2556099. DOI: 10.1371/journal.pone.0003326. View